The rationale engineering of BCR/ABL blockers: an answer to STI571 acquired resistance in leukemia treatment.
Majsterek
Ireneusz J
IJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D004247:DNA / Q000187:drug effects; D004260:DNA Repair; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D014226:Triazenes / Q000494:pharmacology* / Q000627:therapeutic use*
C501822:3-methyl-1,2,3-triazene; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D014226:Triazenes; D000068877:Imatinib Mesylate; D004247:DNA; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl